Five Prime Therapeutics (United States)
- Research works
- 91 ▼ 25% vs 2013–17
- Citations
- 2.6k 29.0 per fractional work
- Top-10% rate
- 36.6% record average 16.5%
- Open access
- 50% world 28%
Not ranked overall: Five Prime Therapeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 8.9×. Every wedge is a field page.
- Economics, Econometrics and Finance 8.9×
- Immunology and Microbiology 5.8×
- Medicine 2.6×
- Psychology 1.3×
- Agricultural and Biological Sciences 0.8×
- Neuroscience 0.8×
- Computer Science 0.6×
- Health Professions 0.5×
- Biochemistry, Genetics and Molecular Biology 0.4×
- Business, Management and Accounting 0.4×
- Social Sciences 0.2×
- Engineering 0.2×
Who are the top researchers at Five Prime Therapeutics (United States)?
Ranked on the composite score, Robert Sikorski and Thomas J. Brennan lead among researchers whose main affiliation is Five Prime Therapeutics (United States).
- 1 Robert Sikorski United States · #227,530 worldwide 440 citations · 16 works
- 2 Thomas J. Brennan United States · #328,345 worldwide 131 citations · 20 works
Which keywords describe research at Five Prime Therapeutics (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Cancer, Metabolism, Obesity, Tumor Microenvironment, Immunity, Therapy, Signaling and Inflammation.
- Insulin Therapy
- Fc Receptors
- Glycemic Control
- Inappropriate Medication Use
- Financial Toxicity
- Cost of Care
- Drug Development Costs
- Antigen Presentation
- Polarization
- Activation
- Patient Compliance
- Innate Immunity
- Medication Adherence
- Chronic Disease Management
- PD-1 and PD-L1
- Fibroblast Growth Factor
- Signaling
- Tumor Microenvironment
- Obesity
- Metabolism
- Cancer
- Inflammation
- Immunity
- Therapy
- FGF21
- Immune Checkpoint Blockade
- Cancer Immunotherapy
- Health Outcomes
- Immunotherapy
- Macrophage
- Treatment Adherence
- Glycosylation
- Pharmaceutical Industry
- Monoclonal Antibodies
- Generic Drugs
- Dendritic Cells
- Tumor Antigen
- Polypharmacy
- Diabetes
- Therapeutic Antibodies
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Cancer12▲ 9.2×13 topics
- Metabolism9▲ 16×7 topics
- Inflammation7▲ 3.4×16 topics
- Obesity6▲ 9.2×6 topics
- Immunity6▲ 20×4 topics
- Tumor Microenvironment6▲ 19×5 topics
- Therapy5▲ 26×2 topics
- Signaling5▲ 49×2 topics
- FGF215▲ 345×1 topic
- Fibroblast Growth Factor5▲ 345×1 topic
- Immune Checkpoint Blockade5▲ 92×1 topic
- PD-1 and PD-L15▲ 92×1 topic
- Cancer Immunotherapy4▲ 35×3 topics
- Chronic Disease Management4▲ 29×4 topics
- Health Outcomes4▲ 18×2 topics
- Medication Adherence4▲ 71×2 topics
- Immunotherapy4▲ 5.9×9 topics
- Innate Immunity3▲ 11×6 topics
- Macrophage3▲ 66×2 topics
- Patient Compliance3▲ 180×1 topic
- Treatment Adherence3▲ 180×1 topic
- Activation3▲ 104×1 topic
- Glycosylation3▲ 16×3 topics
- Polarization3▲ 40×1 topic
- Pharmaceutical Industry3▲ 87×2 topics
- Antigen Presentation3▲ 34×2 topics
- Monoclonal Antibodies3▲ 23×2 topics
- Drug Development Costs3▲ 124×1 topic
- Generic Drugs3▲ 124×1 topic
- Cost of Care3▲ 160×1 topic
- Dendritic Cells3▲ 26×1 topic
- Financial Toxicity3▲ 160×1 topic
- Tumor Antigen3▲ 37×1 topic
- Inappropriate Medication Use2▲ 68×1 topic
- Polypharmacy2▲ 68×1 topic
- Glycemic Control2▲ 20×4 topics
- Diabetes2▲ 4.9×7 topics
- Fc Receptors2▲ 25×1 topic
- Therapeutic Antibodies2▲ 20×1 topic
- Insulin Therapy2▲ 21×3 topics
Which research topics does Five Prime Therapeutics (United States) publish most on?
By volume in 2022–2025: Pharmaceutical Practices and Patient Outcomes, Economic and Financial Impacts of Cancer, Medication Adherence and Compliance and Pharmaceutical Economics and Policy.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Pharmaceutical Practices and Patient Outcomes Geriatrics and Gerontology 2 works
- 2 Economic and Financial Impacts of Cancer Economics and Econometrics 1 works
- 3 Medication Adherence and Compliance Family Practice 1 works
- 4 Pharmaceutical Economics and Policy Economics and Econometrics 1 works
- 5 Cystic Fibrosis Research Advances Pulmonary and Respiratory Medicine 0 works
- 6 Nematode management and characterization studies Plant Science 0 works
- 7 Diabetes Treatment and Management Endocrinology, Diabetes and Metabolism 0 works
- 8 Cardiac, Anesthesia and Surgical Outcomes Cardiology and Cardiovascular Medicine 0 works
- 9 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 0 works
- 10 Bariatric Surgery and Outcomes Surgery 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Five Prime Therapeutics (United States)'s research output changed?
Output in 2018–2022 was 25% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in South San Francisco
- Sunesis (United States)
- Exelixis (United States)
- Kaiser Permanente South San Francisco Medical Center
- Cytokinetics (United States)
- Portola Pharmaceuticals (United States)
- NGM Biopharmaceuticals (United States)
- Rapt Therapeutics (United States)
- Atara Biotherapeutics (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.